IGF1 Human, V44M
Greater than 95.0% as determined by SDS-PAGE.
Description
IGF1 V44M Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 70 amino acids and having a molecular mass of Approximately 7.7 kDa.
The IGF1 V44M is purified by proprietary chromatographic techniques.
Product Specs
The insulin-like growth factors (IGFs), also known as somatomedins, are a family of peptides that play a crucial role in mammalian growth and development. IGF1 is a key mediator of growth hormone's (GH; MIM 139250) growth-promoting effects. Research has shown that growth hormone doesn't directly stimulate sulfate incorporation into cartilage. Instead, it operates through a serum factor initially called 'sulfation factor' and later renamed 'somatomedin' (Daughaday et al., 1972). Three primary somatomedins have been identified: somatomedin C (IGF1), somatomedin A (IGF2; MIM 147470), and somatomedin B (MIM 193190) (Rotwein, 1986; Rosenfeld, 2003).
Recombinant Human IGF1 V44M, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 70 amino acids. It has a molecular weight of approximately 7.7 kDa.
Purification of IGF1 V44M is achieved using proprietary chromatographic methods.
IGF1 V44M is lyophilized from a concentrated 0.2 µm filtered solution in phosphate-buffered saline (PBS).
For reconstitution, it is recommended to dissolve the lyophilized IGF1 V44M in sterile 18 MΩ-cm H2O at a concentration of at least 100 µg/ml. This solution can then be further diluted into other aqueous solutions as needed.
For short-term storage (2-4 weeks), store the reconstituted vial at 4°C. For long-term storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advisable for extended storage. Avoid repeated freeze-thaw cycles.
The purity is determined to be greater than 95.0% as assessed by SDS-PAGE.
GPETLCGAEL VDALQFVCGD RGFYFNKPTG YGSSSRRAPQ TGIMDECCFR SCDLRRLEMY.
Product Science Overview
Insulin-like Growth Factor-1 (IGF-1) is a hormone similar in molecular structure to insulin. It plays a crucial role in childhood growth and continues to have anabolic effects in adults . IGF-1 is produced primarily in the liver and also in other tissues such as the kidney, heart, lung, and various glandular tissues . The mutant variant V44M of IGF-1 refers to a specific mutation where the valine (V) at position 44 is replaced by methionine (M).
IGF-1 is part of a family of peptides known as somatomedins, which are involved in mammalian growth and development . It mediates many of the growth-promoting effects of growth hormone (GH). The V44M mutation in IGF-1 can affect its interaction with IGF-1 receptors and binding proteins, potentially altering its biological activity and stability.
Recombinant human IGF-1, including the V44M mutant, is typically produced using recombinant DNA technology. This involves inserting the gene encoding IGF-1 into a suitable expression system, such as E. coli or yeast, which then produces the protein. The protein is subsequently purified through various chromatographic techniques to ensure its purity and activity.
Recombinant IGF-1, including its mutant forms, is used in various research and clinical applications. It has been studied for its potential to increase insulin sensitivity and improve glycemic control in patients with type II diabetes . Additionally, IGF-1 therapies are being explored for their potential to treat growth failure in children with severe primary IGF-1 deficiency .
